As we gear up toward legalization of marijuana in Canada, data continues to pile up on the potential benefits of CBD oil for psychosis. Early studies likened its effect on the psychotic brain to that of antipsychotics. A critical review of 30 years of data found:
CBD appears to have pharmacological profile similar to that of atypical antipsychotic drugs as seem using behavioral and neurochemical techniques in animal models. Additionally, CBD prevented human experimental psychosis and was effective in open case reports and clinical trials in patients with schizophrenia with a remarkable safety profile…These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.
CBD is a compound in cannabis sativa that does not have the psychoactive effect THC does. In fact, it’s been largely bred out of many strains because it mitigates the ‘high’ that users get from the plant. Many people believe it to be neuroprotective and highly medicinal, with great clinical application for Parkinsons and other diseases of the central nervous system.
Pharmaceutical companies are now trying to patent synthetically manufactured CBD for neurological disorders. It remains to be seen if the synthetic substances act as favourably in clinical use as those found in nature.
A list of other studies supporting a possible therapeutic effect of CBD on psychosis can be found here. Of particular interest, is the data supporting CBD for those with schizophrenias that are resistant to traditional pharmaceutical therapies. Currently these patients have very poor outcomes and the highest rate of suicide, stigmatization, and isolation of any illness.